Johnson & Johnson (JNJ) Profit After Tax (2009 - 2026)
Johnson & Johnson (JNJ) posted Profit After Tax of $5.5 billion for Q2 2026, up 5.71% sequentially from $5.2 billion in Q1 2026, and little changed YoY from $5.5 billion in Q2 2025.
Johnson & Johnson (JNJ) Profit After Tax (2009 - 2026) Analysis & Trends
Johnson & Johnson has reported Profit After Tax for 18 years, with the latest figure at $5.5 billion in Q2 2026.
- Quarterly Profit After Tax changed 0.05% year-over-year to $5.5 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $21.0 billion (down 7.17% YoY) and the FY2025 annual result came in at $26.8 billion, up 90.56% from the prior year.
- Profit After Tax advanced to $5.5 billion in Q2 2026 per JNJ's latest filing, from $5.2 billion in the prior quarter.
- Over five years, Profit After Tax peaked at $26.0 billion in Q4 2023 and troughed at -$491.0 million in Q2 2023.
- A 5-year average of $5.8 billion and a median of $5.0 billion in 2022 frame the typical range for Profit After Tax.
- The sharpest annual moves came in 2023 and 2024: Profit After Tax slumped 109.54% in 2023, then jumped 762.93% in 2024.
- Over 5 years, Profit After Tax stood at $4.5 billion in 2022, then slipped by 7.31% to $4.1 billion in 2023, then dropped by 16.97% to $3.4 billion in 2024, then soared by 49.11% to $5.1 billion in 2025, then gained by 8.17% to $5.5 billion in 2026.
- According to Business Quant data, Profit After Tax over the past three periods registered $5.5 billion, $5.2 billion, and $5.1 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 5.53 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 3.62 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | -1.34 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 3.26 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 2.51 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 2.38 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | -10.50 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | -248.00 Mn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 207.96 Mn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 438.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 5.53 Bn |
| Mar 29, 2026 | 5.24 Bn |
| Dec 28, 2025 | 5.12 Bn |
| Sep 28, 2025 | 5.15 Bn |
| Jun 29, 2025 | 5.54 Bn |
| Mar 30, 2025 | 11.00 Bn |
| Dec 29, 2024 | 3.43 Bn |
| Sep 29, 2024 | 2.69 Bn |
| Jun 30, 2024 | 4.69 Bn |
| Mar 31, 2024 | 3.26 Bn |
| Dec 31, 2023 | 4.13 Bn |
| Oct 1, 2023 | 26.03 Bn |
| Jul 2, 2023 | 5.38 Bn |
| Apr 2, 2023 | -491.00 Mn |
| Jan 1, 2023 | 3.52 Bn |
| Oct 2, 2022 | 4.46 Bn |
| Jul 3, 2022 | 4.81 Bn |
| Apr 3, 2022 | 5.15 Bn |
| Oct 3, 2021 | 3.67 Bn |
| Jul 4, 2021 | 6.28 Bn |